🇺🇸 FDA
Patent

US 8859207

Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same

granted A61KA61K31/165A61K31/167

Quick answer

US patent 8859207 (Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61K, A61K31/165, A61K31/167, A61K31/192, A61K31/195